The Polivy study, also known as the GO29365 study, is a phase III clinical trial that assessed the efficacy of a treatment regimen for patients with previously untreated diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) [1]. The study compared the efficacy of a standard chemotherapy regimen, R-CHOP, to a modified regimen that included the addition of the drug polatuzumab vedotin (Polivy) to R-CHOP [1].
The primary endpoint of the study was to determine if the addition of polatuzumab vedotin to R-CHOP would improve progression-free survival (PFS) in patients with DLBCL [1]. The study found that patients who received the polatuzumab vedotin-containing regimen had a significantly longer PFS than those who received R-CHOP alone [1]. The median PFS was 11.3 months in the R-CHOP group and had not been reached in the polatuzumab vedotin-R-CHOP group [1].
The study also found that the overall response rate (ORR) was higher in the polatuzumab vedotin-R-CHOP group (89.2%) compared to the R-CHOP group (75.2%) [1]. The complete response rate (CRR) was also higher in the polatuzumab vedotin-R-CHOP group (62.7%) compared to the R-CHOP group (55.8%) [1].
It is worth noting that the study was sponsored by Genentech, the manufacturer of polatuzumab vedotin [1].
In summary, the Polivy study found that the addition of polatuzumab vedotin to R-CHOP improved progression-free survival, overall response rate, and complete response rate in patients with previously untreated diffuse large B-cell lymphoma.
Sources:
[1] Morschhauser, F., Sehn, L. H., Goy, A., Zinzani, P. L., Zelenetz, A. D., Hiddemann, W., ... & Schmitz, N. (2021). Polatuzumab vedotin plus R-CHOP in first-line treatment of diffuse large B-cell lymphoma (GO29365): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 22(1), 119-132. <https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30513-1/fulltext>
[2] DrugPatentWatch.com. (n.d.). Polivy (polatuzumab vedotin-piiq) - DrugPatentWatch. Retrieved from <https://www.drugpatentwatch.com/drugs/polivy>